An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects - Wikidata - awgldk - TriplyDB

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects

http://www.wikidata.org/entity/Q31038370

about

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population.Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis.Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses.Autoinjector preference among patients with multiple sclerosis: results from a national survey.Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.Pen devices for self-injection: contrasting measured injection force with users' perceived ease of injection.Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system.Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects

P2860

Q30406774-09437F1C-F12E-487E-BDA4-C91A16DF855C Q30839407-2AC7FC2A-B74D-47F5-A98C-56627D4B2B3A Q34194003-8C8656A4-671E-4441-AFA2-630F39AD8C73 Q35703723-C1ECC7FA-BEED-4752-B57F-36188E2842EC Q35784295-F0C5A442-1BB6-470F-ABAD-8AF4D94A776D Q36340526-A3BA8D65-F98A-403E-A125-2AB6EFD41863 Q36389706-54775AFB-63A7-433A-8364-9225BCDFB035 Q36626213-03E42001-C7E3-4247-B7AC-BACE30397F4F Q37597518-EF05B003-77E1-4346-BD75-5D5BE04C763F Q38244521-5B4ED1A7-1C43-44AC-83F7-C2E3D22D4994 Q38613249-DC759BAB-34AB-4497-AA52-DB17A4C68376 Q43374990-AD89036E-D2F7-4588-B6FD-A19D70B5A9DC Q47262735-B3C7F9DB-2248-4F95-828E-3C3C0C635934 Q47282950-038C9722-F198-47EB-9374-036668D1757A Q48058748-E813C631-854C-48A0-A80C-F6701576AC65 Q48064606-A7D4BB17-7D2C-4AAF-8CE2-A1BE253FBA94 Q49881176-FFB05EC1-B099-4F3B-88AA-B50B6729F2B0 Q52576324-7B49DBFE-8907-46D6-B2B2-C92E18C0873E Q57176982-E6DAB115-F688-4048-91C1-D1D5F6A9CA97 Q59125679-AE7398EF-D510-4043-92AC-0D77189B328B

P2860

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects

http://www.wikidata.org/entity/Q31038370

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

An open-label, multicenter stu ...... in multiple sclerosis subjects

@ast

An open-label, multicenter stu ...... in multiple sclerosis subjects

@en

type

label

An open-label, multicenter stu ...... in multiple sclerosis subjects

@ast

An open-label, multicenter stu ...... in multiple sclerosis subjects

@en

prefLabel

An open-label, multicenter stu ...... in multiple sclerosis subjects

@ast

An open-label, multicenter stu ...... in multiple sclerosis subjects

@en

P1433

Q31038370-57F699F0-455D-4502-ADB4-32EBEA729D0C

P1476

Q31038370-C6BBBA34-AB6E-4717-9CAA-5E87EBB0C2B6

P2093

Q31038370-097CD093-AE1F-4377-A837-3CE765651A3A

Q31038370-1899BFC4-1354-48E2-BB81-C6FE61FA335C

Q31038370-61E78FFD-2A7A-47FB-8C6C-BE253F6B035A

Q31038370-9A49F881-D5E7-4943-9E84-894027D8A95C

Q31038370-BC41E71D-2C6E-4810-9B20-D8BE326682B5

Q31038370-F3E13EC8-7791-438D-9795-AA1EC8F18C43

P2860

Q31038370-2389FB83-CE93-42E4-A081-B52357F8B184

Q31038370-2B64F6F6-C2B0-47C4-B39E-D0D1622F37F5

Q31038370-3661C186-11C9-46C0-B516-857AFB07C6F3

Q31038370-3D69F547-AB3E-4C8A-8246-308693233ACC

Q31038370-4C80BB45-C6C7-493E-B262-0C308DE10E5F

Q31038370-50D34F3A-8CF3-4869-AF46-E72DDAE9C27C

Q31038370-598C5422-A1EF-47EA-B0E3-E048D4E88027

Q31038370-76322529-23A4-41CA-B594-7656CF8D8191

Q31038370-812B4433-9930-472B-8AE4-05FABA7B28DC

Q31038370-9A8595B8-4CAA-4066-A345-8EFC820EA792

P2888

Q31038370-13558D9C-89EE-4650-A034-AB96604B2EFB

P304

Q31038370-87F3AE72-5923-4CA8-81D5-9884CF737963

P31

Q31038370-301451BA-85A6-47F1-9D67-C2B0CAA16E74

P356

Q31038370-BC9F4C6C-62DF-4A22-BBB7-F6C497669791

P478

Q31038370-CE550BCD-B9A2-429B-994C-04FE9B18F3DC

P577

Q31038370-BA37ACAB-8DEC-4EC2-AEAE-D7434D4A0230

P5875

Q31038370-98AFF20D-DBA4-4314-A425-E1945BE66186

P6179

Q31038370-EFABDFAB-9F0C-47E5-A2B5-FACB548E6EBA

P698

Q31038370-49BD86A0-CD8F-4FDC-8E9E-6BCF2CAA208F

P921

Q31038370-7D2B9AEA-8CC3-4CB3-B50F-BBA4FAD2E4C0

Q31038370-F1B7A1CD-4B3B-48C2-A825-B6356A10D5B7

P932

Q31038370-45E8945F-10C7-4B61-8263-CAA9583DA732

P356

1471-2377-11-126

P1433

P1476

An open-label, multicenter stu ...... in multiple sclerosis subjects

@en

P2093

Aaron Deykin

http://www.w3.org/2001/XMLSchema#string

Dianne Tuccillo

http://www.w3.org/2001/XMLSchema#string

Edward Fox

http://www.w3.org/2001/XMLSchema#string

J Theodore Phillips

http://www.w3.org/2001/XMLSchema#string

Shifang Liu

http://www.w3.org/2001/XMLSchema#string

William Grainger

http://www.w3.org/2001/XMLSchema#string

P2860

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.

Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies.

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.

Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues.

P2888

1471-2377-11-126

P304

126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2377-11-126

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51722022

http://www.w3.org/2001/XMLSchema#string

P6179

1012453385

http://www.w3.org/2001/XMLSchema#string

P698

21999176

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

multiple sclerosis

P932

3213083

http://www.w3.org/2001/XMLSchema#string